We found that high ANLN expression was associated with the clinical benefits of ICB therapy (PD-1) in patients with bladder cancer and glioblastoma, while low ANLN expression was associated with the clinical benefits of ICB therapy (PD-L1 or PD-1) in patients with kidney cancer and melanoma. This evidence concerns the gene CD274 and urinary bladder carcinoma.